Valuation: Jade Biosciences, Inc.

Market Cap 1.33B 1.17B 1.08B 994M 1.89B 127B 1.92B 12.86B 5.05B 62.7B 5.01B 4.9B 216B P/E 2026 *
-8.64x
P/E 2027 * -8.72x
Enterprise Value 1.08B 945M 872M 805M 1.53B 103B 1.55B 10.42B 4.09B 50.78B 4.06B 3.97B 175B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-6.81%
1 week-1.64%
Current month-5.72%
1 month+37.29%
3 months+17.10%
6 months+51.15%
Current year+35.77%
1 week 19.76
Extreme 19.76
23.36
1 month 15.12
Extreme 15.12
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 27/04/2025
Director of Finance/CFO 38 13/07/2025
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 50 27/04/2025
Director/Board Member 42 27/04/2025
Chairman 57 27/04/2025
Date Insider Type Main position Quantity % Market Cap.
06-24Free

Director

47,675 0.0966%
06-08Free

Director

34,843 0.0706%
06-08Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-6.81%-1.64%+99.14% - 1.33B
+0.58%+3.79%+4.16%+11.62% 50.44B
-2.22%-1.64%+385.40%+586.81% 40.63B
-0.54%+0.91%+25.57%-5.28% 34.88B
-1.36%-3.48%+17.88%+55.14% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-1.81%+0.94% - - 17.11B
+0.51%-4.75%+63.97%+122.60% 15.29B
-9.37%-29.97%+37.45%+39.42% 10.62B
+0.23%-0.26%+15.51%+21.54% 13.74B
Average -1.86%-1.46%+72.62%+108.38% 24.4B
Weighted average by Cap. -0.73%-0.00%+84.63%+131.30%

Financials

2026 *2027 *
Net sales - -
Net income -173M -152M -140M -129M -245M -16.52B -249M -1.67B -656M -8.14B -650M -636M -27.98B -191M -167M -154M -142M -270M -18.23B -275M -1.84B -724M -8.98B -718M -702M -30.88B
Net Debt -254M -222M -205M -189M -358M -24.18B -364M -2.44B -960M -11.91B -952M -931M -40.95B -300M -263M -242M -224M -425M -28.64B -432M -2.89B -1.14B -14.11B -1.13B -1.1B -48.5B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
10/07/26 US$20.95 -6.81% 1,413,163
09/07/26 US$22.48 -0.22% 646,408
08/07/26 US$22.53 +0.36% 878,516
07/07/26 US$22.45 +5.40% 1,042,841
06/07/26 US$21.30 -0.98% 1,056,288
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
22.48USD
Average target price
48.50USD
Spread / Average Target
+115.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock